2024】最佳伴手禮首選》這款長輩超愛

Weight | 合法藥品大搜索

Weight

由MMukherjee著作·2018·被引用118次—...IVreslizumabwassuperiortofixed-doseSCmepolizumabin...ofΔbetweenbeforeandaftertreatment,mepolizumabvs.reslizumab, ...

 Weight

Rationale: Clinical benefits of fixed-dose 100-mg subcutaneous (SC) mepolizumab in prednisone-dependent patients are modest when sputum eosinophilia is not adequately controlled.

Objectives: This study compared treatment response of weight-adjusted intravenous (IV) reslizumab in patients previously treated with 100-mg SC mepolizumab.

Methods: Ten prednisone-dependent patients with asthma (sputum eosinophils >3% and blood eosinophils >300 cells/μl), who had previously received mepolizumab (100 mg SC dosed every 4 wk [Q4W]) for at least 1 year, received two infusions of placebo (Q4W) followed by four infusions of 3.0 mg/kg reslizumab Q4W in a single-blind, placebo-controlled sequential trial. Primary outcomes were reduction of eosinophils in sputum and blood. Additional outcomes included FEV1, asthma control questionnaire, eosinophil peroxidase, IL-5, sputum and blood innate...

閱讀更多

dupilumab vs mepolizumab Mepolizumab benralizumab benralizumab vs dupilumab benralizumab vs omalizumab nucala vs fasenra vs dupixent benralizumab review xolair and dupixent combination EAACI biologicals Guidelines recommendations for severe asthma Mepolizumab benralizumab健保 benralizumab中文 benralizumab機轉 mepolizumab健保 Mepolizumab benralizumab omalizumab健保 nucala健保價 阿莫西林副作用 冠脂妥副作用 類固醇眼藥水有哪些 得蘇錠０．５公絲（哈泊度）副作用 antone tablets副作用 衛 克 感 副作用 得克膚軟膏價錢 Sulfamethoxazole
Efficacy, adverse events, and inter | 合法藥品大搜索
由 DP Henriksen 著作 · 2018 · 被引用 30 次 — Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review ... Read More
Efficacy and safety of treatment with biologicals ... | 合法藥品大搜索
由 I Agache 著作 · 2020 · 被引用 57 次 — Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A ... Read More
Reslizumab and mepolizumab for moderate | 合法藥品大搜索
由 K Yan 著作 · 2019 · 被引用 4 次 — Materials & methods: Eligible studies evaluated reslizumab and mepolizumab in patients with inadequately-controlled severe eosinophilic ast ... Read More
Higher Binding Affinity and in vitro Potency of Reslizumab for ... | 合法藥品大搜索
由 M Liddament 著作 · 2019 · 被引用 15 次 — Reslizumab and mepolizumab are recently approved monoclonal antibodies for the treatment of severe (uncontrolled) eosinophilic asthma. Both are effective in ... Read More
Mabs for treating asthma | 合法藥品大搜索
由 E Ridolo 著作 · 2020 · 被引用 3 次 — They include monoclonal antibodies that target the Th2-pathway cytokines, such as IL-5 (mepolizumab and reslizumab) or its receptor ( ... Read More
Weight | 合法藥品大搜索
由 M Mukherjee 著作 · 2018 · 被引用 118 次 — ... IV reslizumab was superior to fixed-dose SC mepolizumab in ... of Δ between before and after treatment, mepolizumab vs. reslizumab, ... Read More
Efficacy, adverse events, and inter-drug ... | 合法藥品大搜索
由 DP Henriksen 著作 · 2018 · 被引用 30 次 — Conclusions: Mepolizumab and reslizumab provide significant and clinically relevant improvements in exacerbation rate and OCS reduction. Read More
Reslizumab and mepolizumab for moderate | 合法藥品大搜索
由 K Yan 著作 · 2019 · 被引用 4 次 — Reslizumab and mepolizumab are anti-IL5 biologics for the treatment of severe eosinophilic asthma. No head-to-head comparisons of the relative ... Read More
Mepolizumab | 合法藥品大搜索
2017年9月21日 — By the year 2025, there may be up to 400 million people with asthma worldwide. Mepolizumab, reslizumab and benralizumab are new 'anti-IL-5' ... Read More
Efficacy and safety of treatment with biologicals (benralizumab ... | 合法藥品大搜索
由 I Agache 著作 · 2020 · 被引用 57 次 — Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic ... Read More
相關資訊整理

【肺昇朗注射液劑30毫克】FASENRA適用於嗜酸性白血球表現型的嚴重氣喘成人病人，做為附加維持治療。

藥品名稱:肺昇朗注射液劑30毫克許可證字號:衛部菌疫輸字第001101號許可證種類:菌　疫適應症:FASENRA適用於嗜酸性白血球表現...